CRVS enters July with a striking contradiction at its core: the stock has rallied 18% in a week and 20% over the past month to close at $14.94, yet short sellers have not retreated — they have added to positions.
Short interest has climbed to 25.4% of the free float, up roughly 6.5% on the week and nearly 9% over the past month. That combination — a rising price and rising short interest — sets up the central tension in this name right now. Bears are not capitulating into strength; they are leaning harder against it. The ORTEX short score reinforces this picture: it jumped from 78.1 to 81.1 between June 22 and June 30, a move that puts CRVS firmly in the top tier of short-conviction names in the universe. Fourteen days to cover, per official FINRA data, means any disorderly unwind would take time to clear.
The lending market, however, tells a more nuanced story. Availability has tightened sharply over the past week — dropping from around 125% to 89%, a 42% tightening in seven days — though it remains in the "normal to slightly tight" range overall. The borrow is not expensive: cost to borrow is running near 0.5%, barely changed, and well below the distressed territory that tends to precede forced covering. Crucially, borrow availability has never come close to the 52-week low of 46.8%, meaning the lending pool still has room for new shorts to enter. There is no mechanical squeeze pressure here yet — just a rising claim on available supply. Options positioning leans the other way entirely. The put/call ratio has fallen to 0.27, close to its 52-week low of 0.23 and roughly a standard deviation below its 20-day average of 0.31. Call demand is running unusually hot, suggesting options traders are betting on further upside even as short sellers pile in.
On the Street, analysts are uniformly bullish — all six covering analysts carry buy-equivalent ratings — but their price targets tell a wide story. Goldman Sachs initiated coverage in mid-April with a $40 target, the highest on the panel. Jefferies and Oppenheimer both hold targets in the $33–$42 range. Even at the current $14.94, the implied upside to the consensus mean is substantial, though the analyst data is now roughly six weeks stale. The bull case rests on the immune-modulation pipeline — particularly atopic dermatitis trial results described as highly effective with minimal adverse effects — and projected market penetration of 30%. Bears counter with pipeline concentration risk: one primary therapy, limited late-stage diversification, and a cash runway that requires continued execution. Corvus is pre-revenue, so traditional valuation multiples are not meaningful guides here. What matters is clinical progress and capital durability.
Insiders have been buying consistently, which adds texture to the bullish analyst chorus. The CEO and Founder Richard Miller bought shares in May at around $12. A director added $250k worth at $11.53 in June. Net insider purchases over the past 90 days total roughly $334k. These are not large in absolute terms for a company of this profile, but the direction is unambiguous: those closest to the pipeline have been accumulating through the rally rather than selling into it.
Recent earnings history is volatile enough to warrant attention. The last four quarterly data events showed swings ranging from a 22% single-day decline to a near-7% gain, with meaningful five-day follow-through in both directions. The next earnings event is scheduled for August 4. That date gives a month for the short interest / options divergence to play out before the next scheduled binary moment.
The setup heading into August is one of competing convictions: options traders loading calls, insiders buying, and analysts bullish, all against a short base that has grown steadily through the recent rally — how the stock responds when both sides face their next inflection point is what this note is really about.
See the live data behind this article on ORTEX.
Open CRVS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
